Home / Industry News / 2016 / Natco Pharma Launches First Generic Hep C Med in India

Natco Pharma Launches First Generic Hep C Med in India

Source: Business Standard

Jan 02, 2017

Hyderabad-based Natco Pharma has launched the first generic version of Gilead's Sofosbuvir in Nepal.

Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination is sold by Gilead Sciences, under the brand name Epclusa.

Natco will market Sofosbuvir under the name Velpanat as a single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

Read the Business Standard coverage

Show More Content

More News:

India's Glenmark to launch US spin-off

02/15/2019

Generic drugmaker Glenmark Pharmaceuticals plans to spin off its innovation business into a new company in the U.S. which will offer branded drugs.
Internal rap video adds to Insys woes in opioid trial

02/14/2019

During the racketeering trial for Insys Therapeutics founder, federal prosecutors shared a five-minute in-house rap video that they say was designed to motivate employees to push sales of a highly addictive fentanyl spray.
FDA issues first warning letter under DSCA for opioid distribution

02/13/2019

McKesson Corp is back in the spotlight for opioid-related violations — this time involving rules under the 2013 Drug Supply Chain Security Act.
Antidepressant made with party drug gets FDA panel’s backing

02/13/2019

An experimental nasal spray developed by Johnson & Johnson to treat depression could be headed for FDA approval.
Gilead liver med flunks key phase 3 trial

02/12/2019

The company's most advanced candidate for a treatment of NASH prospect selonsertib, what some consider pharma's next big market, has failed a late-stage trial.
Mylan's Advair generic starts at one-third price

02/12/2019

Mylan's generic version of GlaxoSmithKline’s asthma treatment, the first generic to be launched, is priced 70 percent lower than the blockbuster version.
New 24-hour flu drug may not be a silver bullet after all

02/11/2019

The drug, developed by Japan’s Shionogi and Co. and called Xofluza, was designed to snuff out the flu in 24 hours with one dose.
Sanofi and Regeneron slash cost of cholesterol drug by 60 percent

02/11/2019

As many companies fall into the public spotlight for raising drug prices, two companies have dramatically decreased the cost of a cholesterol medication.
Amsterdam hospital to make its own orphan drug generics

02/11/2019

The Amsterdam University Medical Center will use a 5 million euros donation to make generic versions of orphan medicines.
AbbVie, Teneobio partner on Multiple Myeloma

02/11/2019

AbbVie and Teneobio announced a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.

Pharma Manufacturing

Join the discussion

Comments

FDA issues first warning letter under DSCA for opioid distribution

McKesson Corp is back in the spotlight for opioid-related violations —…

Infamous pharma co. files for bankruptcy

Novum Pharma, a Chicago-based pharmaceutical company that made headlines…

New 24-hour flu drug may not be a silver bullet after all

The drug, developed by Japan’s Shionogi and Co. and called Xofluza, was…

Vanda sues FDA over mandate to test drug on dogs

Vanda Pharmaceuticals is bringing a lawsuit against the FDA, saying the…

Antidepressant made with party drug gets FDA panel’s backing

An experimental nasal spray developed by Johnson & Johnson to treat…

Top 5 Drugs With the Biggest Growth Potential in 2019

In the coming year, several drugs that treat a range of diseases will far…

FDA issues six observations for Lupin plant

The U.S. FDA has issued six observations after the inspection of Lupin's…

Bayer to shutter Pennsylvania site, jeopardizing 600 jobs

Amid restructuring efforts related to its $63 billion acquisition of…

FDA warns of blood pressure med shortage

FDA Commissioner Scott Gottlieb and CDER Director Janet Woodcock released…

Former pharma exec accused of giving a lap dance as part of an opioid kickback scheme

A former sales executive from Insys Therapeutics reportedly once gave a…

Puerto Rico Pharma: Battered but Unbroken

One year after Hurricane Maria, Puerto Rico's pharma industry is standing…

Top Pharma Manufacturing Predictions for 2019

From new tech to innovative business models and shifting regulations,…

Top 5 Drugs With the Biggest Growth Potential in 2019

In the coming year, several drugs that treat a range of diseases will far…

Boehringer cuts nearly 300 jobs in France

The company's French workforce will see 327 jobs cut but will also see 32…

Roche R&D exec leaves pharma for biotech, joins Voyager Therapeutics

Voyager Therapeutics appoints Omar Khwaja as its chief medical officer,…

Weighing and Dispensing: Do it Right

The weighroom is the entry point to manufacturing and a transition point…

CAPA and Root Cause Analysis

Recent FDA Warning Letters have cited insufficient corrective and…

Annual Product Reviews: How to Conduct an Effective Annual Product Quality Review

More than just a regulatory requirement, an APR helps the manufacturer to…

USP Updates <61> and <62> for Microbial Testing of Non-Steriles

Significant changes include more clarity on enumberation and specified…

Serialization and the Drug Quality & Security Act

The supply chain for genuine pharmaceuticals has grown longer, and every…